Abstract: The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).

Abstract: The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).

Abstract: Reactive oxygen species (ROS) generated with noninvasive ultrasound and sonosensitizers, potently synergize with selected immunomodulators to hyperactivate dendritic cells and macrophages at desired locations and times within the body. Together with the tumor antigens provided by dying/dead tumor cells, these signals can result in activation of adaptive immune responses. This approach is useful for eliciting T cell responses within tumors present in any tissue of the body.

Abstract: The invention provides solid, self-emulsifying compositions for oral administration. The compositions can comprise a population of particles comprising a cannabinoid or a terpene, a surfactant, and a solid carrier. The invention also encompasses methods for the preparation and use thereof.

Abstract: The invention is directed to a nanoprecipitate comprising a cannabinoid or a terpene, or combination thereof, a process of preparing the nanoprecipitate, and oral formulations comprising the nanoprecipitate, including beverage additives and edibles.

Abstract: The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).